Compounds > bromotubercidin
Page last updated: 2024-11-07

bromotubercidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Bromotubercidin is a synthetic nucleoside analog of tubercidin. It is a potent inhibitor of adenosine deaminase (ADA), an enzyme that breaks down adenosine. This property makes bromotubercidin a potential therapeutic agent for the treatment of diseases that involve ADA deficiency, such as severe combined immunodeficiency (SCID). Bromotubercidin has also been shown to have anti-inflammatory and anti-cancer activity. Its synthesis involves the bromination of tubercidin, which can be obtained from natural sources. Research on bromotubercidin focuses on its potential as a drug candidate, studying its pharmacokinetic properties, efficacy in various models of disease, and safety in preclinical studies.'

Cross-References

ID SourceID
PubMed CID97186
CHEMBL ID62099
SCHEMBL ID2786440
MeSH IDM0040419

Synonyms (27)

Synonym
5-bromo-7-pentofuranosyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine
(2r,3r,4s,5r)-2-(4-amino-5-bromo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
5-bromotubercidin
7h-pyrrolo(2,3-d)pyrimidin-4-amine, 5-bromo-7-beta-d-ribofuranosyl-
bromotubercidin
21193-80-6
tubercidin, 5-bromo-
CHEMBL62099 ,
(2r,3r,4s,5r)-2-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2r,3r,4s,5r)-2-(4-amino-5-bromo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
bdbm50000300
(2r,3r,4s,5r)-2-(4-amino-5-bromo-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
2-(4-amino-5-bromo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol (br-tub)
2-(4-amino-5-bromo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol(5-bromotubercidin)
2-(4-amino-5-bromo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
5-bromotubericidin
nsc 103802
bromotubercidin; nsc 103802; ac1l6fwl; ac1q26l1; ar-1g7497;(2r,3r,4s,5r)-2-(4-amino-5-bromo-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
SCHEMBL2786440
AKOS030228349
CS-0188232
mfcd22124434
(2r,3r,4s,5r)-2-(4-amino-5-bromo-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
5-bromo-7-beta-d-ribofuranosyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine
5-bromo-7-ss-d-ribofuranosyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine
AS-77775
(2r,3r,4s,5r)-2-{4-amino-5-bromo-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-5-(hydroxymethyl)oxolane-3,4-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)8,317,640.00000.00020.552110.0000AID34006
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)8,317,640.00000.00070.03740.0957AID34006
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)8,317,640.00000.00240.68169.0000AID34006
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)8,317,640.00000.00120.48289.0000AID34006
Adenosine kinaseHomo sapiens (human)IC50 (µMol)4,163,612.56000.00050.605210.0000AID33985; AID33990; AID33993; AID34006
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID83889Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID225769Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID90952Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF).1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID97510In vitro antiproliferative effect against growth rate of L1210 cells at 100 uM concentration1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID80106Tested for antiviral activity against human cytomegalovirus by plaque assay1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID228410Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID229059Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID96214Cytotoxicity against human neoplastic cell line(KB cells)1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID229230Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID33985Inhibition of recombinant human adenosine kinase2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.
AID224918Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID90612Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID229022Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID34006Concentration required for 50% inhibition of the adenosine kinase (AK) activity.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A TOPS-MODE approach to predict adenosine kinase inhibition.
AID98751In vitro inhibition of L1210 cell growth to half of the control rate1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID84959Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID90616Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID91311Cytotoxic activity against HFF cells.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID90982Cytotoxic activity against KB cells.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID90613Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID91293Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and antiviral activity of certain 4- and 4,5-disubstituted 7-[(2-hydroxyethoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID220038Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID226343Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID96381Tested for the inhibition of KB cell growth1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID220035Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID87343Concentration required to decrease the growth rate to 50% of control was evaluated against HSV-1 by using plaque reduction assay.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID98500Tested for in vitro cell growth inhibition of L1210 cells1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID229232Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID98167Concentration required to decrease the growth rate to 50% of control was evaluated by determining their ability to inhibit growth of L1210 cells in vitro.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID87304Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID97385In vitro inhibition of L1210 cell growth.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines.
AID96660Dose required to inhibit proliferation of L-1210 Cells by 50%1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID80113Tested for antiviral activity against human cytomegalovirus by yield reduction assay1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID85868Tested for antiviral activity against Herpes simplex virus type-1 using plaque assay1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID90618Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using yield reduction assay.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID167327Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID82420Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Synthesis, antiproliferative, and antiviral activity of 4-amino-1-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyridazin-7(6H)-one and related derivatives.
AID33993Inhibition concentration against human adenosine kinase2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
AID382097Inhibition of adenosine kinase2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
A CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues.
AID90979Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.
AID33990Inhibition of human adenosine kinase activity2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's5 (38.46)18.2507
2000's5 (38.46)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		3.5990antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		1.9710pyrrole;
secondary amine
toyocamycin
Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.		3.150antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
nsc 65346
sangivamycin: RN given refers to parent cpd. sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.		3.150nucleoside analogueprotein kinase inhibitor
n-chlorosuccinimide
N-chlorosuccinimide : A five-membered cyclic dicarboximide compound having a chloro substituent on the nitrogen atom.		1.9510dicarboximide;
pyrrolidinone
ribavirin
Rebetron: Rebetron is tradename		1.96101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		210adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
bromosuccinimide
Bromosuccinimide: A brominating agent that replaces hydrogen atoms in benzylic or allylic positions. It is used in the oxidation of secondary alcohols to ketones and in controlled low-energy brominations. (From Miall's Dictionary of Chemistry, 5th ed; Hawley's Condensed Chemical Dictionary, 12th ed,).		1.9510dicarboximide;
organobromine compound;
pyrrolidinone		reagent
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		3.2460organoiodine compound
5-chlorotubercidin
[no description available]		3.3770
4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine
4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine: structure given in first source; 5-bromotubercidin in which the ribose is replaced by 2-hydroxyethoxymethyl		2.3820
5'-deoxytoyocamycin
5'-deoxytoyocamycin: from Streptomyces sp. A14345; structure given in first source		2.7130
5'-amino-5'-deoxyadenosine
[no description available]		210
adenosine kinase
Adenosine Kinase: An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20.		2.0410
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.67302-aminopurines;
oxopurine		antimetabolite;
antiviral drug
ganciclovir
[no description available]		2.89402-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
7-deazainosine
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		02.8940
Cytomegalic Inclusion Disease
[description not available]		02.3820
Leukemia L 1210
[description not available]		02.3820
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		02.3820
Carcinoma, Epidermoid
[description not available]		01.9810
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9810
Absence Seizure
[description not available]		0210
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		0210
Microbial Superinvasion
[description not available]		0210